Warning:
Invokana®

linked to Amputation & Fournier's Gangrene.

In August 2018, the FDA issued a nationwide warning about the increased risk for Invokana® and all SGLT2 inhibitor patients of a serious side effect called Fournier’s gangrene which is a devastating genital flesh eating bacteria disease. Invokana® is a prescription medication in the class of drugs known as Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors). This class of type-2 diabetes drugs also includes Invokamet, Invokamet XR,Sulisent, Farxiga, Xigduo XR, Qtern, Jardiance, Glyxambi, Synjardy Steglatro, Segluromet and Steglujan. These drugs are designed to block glucose from entering the bloodstream and about 1.7 million people received prescriptions in 2017. However, SGLT2 inhibitors have been linked to very serious injuries in patients.

Injuries linked to SGLT2 Inhibitors
include:

  • Fournier’s Gangrene

  • Lower Limb Amputation

  • Diabetic Ketoacidosis

  • Pancreatitis

  • Bladder Cancer

  • Death

  • Heart conditions/Stroke

  • Kidney failure

The FDA has Warned of Safety Risks

Along with the 2018 warning about Fournier’s gangrene there have been numerous other warnings.

2017 – FDA required a black box warning on Invokana, Invokamet and Invokamet XR,regarding the increased risk of leg and foot amputations.

2016 – FDA strengthens warnings regarding the risk of acute kidney injury.

2015 – FDA warned of SGLT2 Inhibitors causing too much acid in the blood, serious urinary tract infections and ketoacidosis.

Numerous lawsuits against the manufacturers of SGLT2 drugs have be brought by injured patients nationwide seeking financial compensation. 

Do not stop taking any medication without first consulting with your medical health provider.

Free Legal Consultation

  • This field is for validation purposes and should be left unchanged.

Know Your Rights.

For over 75 combined years, our legal team has successfully helped thousands of victims and families. If you or a loved one experienced injuries while using Invokana® or SGLT2 Inhibitors, call us at 877-535-5750 or fill out the form above for a free consultation.